Cardiovascular outcomes in the comparative hypertension drug trials: More consensus than controversy

Singapore Medical Journal

Volumn 49, Issue 8, 2008, Pages 599-606

  Ong, Hean Teik ^a  

^a HT Ong Heart Clinic   (Malaysia)

Author keywords

Anti hypertensive drugs; Blood pressure control; Cardiovascular outcomes; Drug trials; Hypertension

Indexed keywords

AMILORIDE; AMLODIPINE; ATENOLOL; CAPTOPRIL; CHLORTALIDONE; DILTIAZEM; DOXAZOSIN; ENALAPRIL; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; NIFEDIPINE; PERINDOPRIL; PLACEBO; THIAZIDE DIURETIC AGENT; VALSARTAN; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR EFFECT; CLINICAL STUDY; CLINICAL TRIAL; DRUG EFFECT; DRUG SAFETY; HEART FAILURE; HEART PROTECTION; HUMAN; HYPERTENSION; REVIEW; STROKE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CLINICAL TRIALS AS TOPIC; DIURETICS; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 51549115092     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998; 317:713-20.
2. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353:611-6.
3. Hansson L, Lindholm LH, Ekbom T, et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354:1751-6.
4. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356:366-72.
5. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) Study. Lancet 2000; 356: 359-65.
6. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003.
7. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-97.
8. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2003; 42:239-46.
9. Wing LMH, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin coverting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348:583-92.
10. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled ONset Verapamil INvestigation of Cardiovascular End points (CONVINCE) trial. JAMA 2003; 289:2073-82.
11. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The international Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA 2003; 290:2805-16.
12. Julius S, Kjeldsen SE, Weber M. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363:2022-31.
13. Yui Y, Sumiyoshi T, Kodama K, et al. Comparison of nifedipine retard with angiotensin-converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMICB) randomized trial. Hypertens Res 2004; 27:181-91.
14. Dahlof B, Sever PS, Poulter NR. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as require versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366:895-906.
15. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317:703-13.
16. Kendall MJ. Conventional versus newer antihypertensive therapies - a draw. Lancet 1999; 354:1744-5.
17. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92:1326-31.
18. Shinoda E, Yui Y, Kodama K, et al. Japan Multicenter Investigation for Cardiovascular Diseases-B Study Group. Quantitative coronary angiogram analysis: nifedipine retard versus angiotensin-converting enzyme inhibitors (JMIC-B side arm study). Hypertension 2005; 45:1153-8.
19. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292:2217-26.
20. Pepine CJ. What is the optimal blood pressure and drug therapy for patients with coronary artery disease? JAMA 2004; 292:2271-3.
21. Pitt B, Byington RP, Furberg CD. Effect of amlodipine on the progression of atherosclerosis and occurrence of clinical events. Circulation 2000; 102:1503-10.
22. Poulter NR, Wedel H, Dahlof B. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366:907-13.
23. Daviglus ML, Liu K. Today's Agenda. We must focus on achieving favorable levels of all risk factors simultaneously. Arch Intern Med 2004; 164:2086-7.
24. Staessen JA, Birkenhager WH. Evidence that new antihypertensives are superior to older drugs. Lancet 2005; 366:869-71.
25. Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA 1997; 278: 212-6.
26. Otterstad JE, Ford I. The effect of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction. How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta-blocker trials? Eur J Heart Fail 2002; 4:501-6.
27. HT Ong. The statin studies : from targeting hypercholesterolemia to targeting the high-risk patient. Q J Med 2005; 98:599-614.
28. Duerden M. ASCOT-BPLA. Lancet 2006; 367:206.
29. Cave JA. ASCOT: A tale of two treatment regimes. Is ASCOT all it's cracked up to be? BMJ 2005; 331:1023.
30. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000; 283:1967-75.
31. Barzilay JI, Davis BR, Bettencourt J, et al. Cardiovascular outcomes using doxazosin vs chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT Study. J Clin Hypertens 2004; 6:116-25.
32. Whelton PK, Barzilay J, Cushman WC, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165:1401-9.
33. Rahman M, Pressel S, Davis BR, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the ALLHAT study. Arch Intern Med 2005; 165:936-46.
34. Wright JT, Dunn JK, Cutler JA, et. Outcomes in hypertensive black and nonblack patients treated with Chlorthalidone, Amlodipine, and Lisinopril. JAMA 2005; 293:1595-607.
35. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002; 4:393-504.
36. Williams B. Drug treatment for hypertension: most patients will need a treatment cocktail - including a thiazide diuretic. BMJ 2003; 326:61-2.
37. Appel LJ. The verdict from ALLHAT - Thiazide diuretics are the preferred initial therapy for hypertension. JAMA 2002; 288:3039-42.
38. Salvetti A, Ghiadoni L. Guidelines for antihypertensive treatment: An update after the ALLHAT study. J Am Soc Nephrol 2004; 15:S51-4.
39. Frohlich ED. Treating hypertension-what are we to believe? N Engl J Med 2003; 348:639-41.
40. Messerli FH, Grossman E, Lever AF. Do thiazide diuretics confer specific protection against strokes? Arch Intern Med 2003; 163:2557-60.
41. Opie LH, Schall R. Evidence-based evaluation of calcium channel blockers for hypertension. J Am Coll Cardiol 2002; 39:315-22.
42. Lindholm LH, Carlberg B, Samuelsson O. Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366:1545-53.
43. Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006; 174:1737-42.
44. Kjeldsen SE, Julius S, Brunner H, et al. Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE Trial. The Valsarten Antihypertensive Long-term Use Evaluation. Blood Press 2001; 10:83-91.
45. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363:2049-51.
46. Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 2006; 12:239-45.
47. Krousel-Wood M, Thomas S, Muntner P, Morisky D. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol 2004; 19:357-62.
48. Burke TA, Sturkenboom MC, Lu SE, et al. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens 2006; 24:1193-200.
49. Bourgault C, Senecal M, Brisson M, Marentette MA, Gregoire JP. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. J Hum Hypertens 2005; 19:607-13.
50. Fogari R, Zoppi A. Effect of antihypertensive agents on quality of life in the elderly. Drugs Aging 2004; 21:377-93.
51. Marentette MA, Gerth WC, Billings DK, Zarnke KB. Antihypertensive persistence and drug class. Can J Cardiol 2002; 18:649-56.
52. Ong HT. The JNC 7 hypertension guidelines. JAMA 2003; 290:1312.
53. Taira DA, Wong KS Frech-Tamas F, Chung RS. Copayment level and compliance with antihypertensive medication : analysis and policy implications for managed care. Am J Manag Care 2006; 12:678-83.
54. Hsu J, Price M, Huang J, et al. Unintended consequences of caps on Medicare drug benefits. N Engl J Med 2006; 354:2349-59.
55. Abramson J, Starfield B. The effect of conflict of interest on biomedical research and clinical practice guidelines: Can we trust the evidence in evidence-based medicine? J Am Board Fam Pract 2005; 18:414-8.
56. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003; 326:1167-70.
57. Ridker PM, Torres J. Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005. JAMA 2006; 295:2270-4.
58. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21:1055-76.
59. Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362:1527-35.
60. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-53.
61. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362:782-8.
62. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358:1033-41.
63. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-13.
64. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345:1291-7.
65. Alder AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321:412-9.
66. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-72.
67. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-53.
68. Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organisation (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21:1983-92.
69. Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004 - BHS IV. J Hum Hypertens 2004; 18:139-85.
70. Wright JT, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 2002; 288:2421-31.
71. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351:2058-68.
72. Messerli FH, Mancia G, Conti CR, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144:884-93.
73. Hedblad B, Wikstrand J, Janzon L, Wedel H, Berglund G. Lowdose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001; 103:1721-6.
74. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta-blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318:1730-7.
75. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992; 327:685-91.
76. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353:2001-7.
77. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective Effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-60.
78. Parving HH, Lehnert H, Mortensen JB, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-8.
79. Brenner BM, Cooper ME, Zeeuw D de, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-9.
80. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004; 364:1684-9.
81. Williams B. Treating hypertension: it is not how you start but where you end that matters. J Hypertens 2003; 21:455-7.
82. Yusuf S. Preventing vascular events due to elevated blood pressure. Circulation 2006; 113:2166-8.